| 2026-08-17 | Press release | Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors |
| 2026-08-17 | Press release | Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors |
| 2026-08-03 | Press release | Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health |
| 2026-08-03 | Press release | Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health |
| 2026-06-03 | Press release | Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, a |
| 2026-06-03 | Press release | Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, a |
| 2026-05-26 | Press release | Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza |
| 2026-05-26 | Press release | Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza May 26, 2026 |
| 2026-05-26 | Press release | Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza |
| 2026-05-26 | Press release | Download as PDF |
| 2026-05-15 | Press release | Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results |
| 2026-05-15 | Press release | Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results |
| 2026-05-15 | Press release | PDF |
| 2026-04-02 | Press release | Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive |
| 2026-04-02 | Press release | Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive April |
| 2026-04-02 | Press release | Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive |
| 2026-03-31 | Press release | Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs |
| 2026-03-31 | Press release | Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs |
| 2026-03-09 | Press release | First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment |
| 2026-03-09 | Press release | First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment Marc |
| 2026-03-09 | Press release | First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment |
| 2026-02-19 | Press release | Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiv |
| 2026-02-19 | Press release | Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiv |
| 2026-02-19 | Press release | Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiv |
| 2025-12-18 | Press release | Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with |
| 2025-12-18 | Press release | Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with |
| 2025-12-18 | Press release | Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with |
| 2025-12-01 | Press release | Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference |
| 2025-12-01 | Press release | Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference December 1, 2025 |
| 2025-12-01 | Press release | Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference |
| 2025-11-14 | Press release | Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Pro |
| 2025-11-14 | Press release | Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Pro |
| 2025-10-30 | Press release | Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules |
| 2025-10-30 | Press release | Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules |
| 2025-10-27 | Press release | Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program |
| 2025-10-27 | Press release | Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program |
| 2025-10-02 | Press release | Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference |
| 2025-10-02 | Press release | Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference October 2, 2025 |
| 2025-10-02 | Press release | Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference |
| 2025-09-15 | Press release | Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasd |